AbbVie strikes $10.9B deal for Apogee Therapeutics

AbbVie said Monday it agreed to acquire Apogee Therapeutics for $10.9 billion in cash.

Why it matters: The deal gives AbbVie a credible challenger to Sanofi's blockbuster Dupixent in atopic dermatitis.